Arcutis Q3 revenue rises 45% to $143.9 million; 2026 sales guidance raised
Arcutis reported third-quarter 2026 product revenue of $143.9 million, up 45% from $99.2 million a year earlier, and raised its full-year 2026 net product sales guidance to $535 million–$545 million from $525 million–$540 million. Net income was $8.8 million, or $0.06 diluted earnings per share, compared with $7.4 million and $0.06 a year earlier, while selling, general, and administrative expenses rose to $99.6 million from $62.4 million.
Key points
- Q3 2026 product revenue of $143.9 million, up 45% year over year and 11% sequentially
- Full-year 2026 net product sales guidance raised to $535 million–$545 million from $525 million–$540 million
- Net income of $8.8 million, or $0.06 diluted EPS, versus $7.4 million, or $0.06, in Q3 2025
- SG&A expenses of $99.6 million versus $62.4 million, driven by the Skin to Believe In campaign and sales force expansion; operating cash flow of $18.9 million
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.